Conference Reports for NATAP

Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) Taipei, Taiwan February 16-19, 2012 Back

COMBINATION THERAPY OF TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH HCV GENOTYPE 1 INFECTION WITH DACLATASVIR (DCV; BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN       Reported by Jules Levin 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International Convention Center, February 16-19, 2012   IZUMI N,1 ASAHINA Y,1 YOKOSUKA O,2 IMAZAKI F,2 KAWADA N,3 TAMORI A,3 OSAKI Y,4 KIMURA T,4 YAMAMOTO K,5 SATA M,6 1MUSASHINO RED CROSS HOSPITAL, TOKYO, JAPAN; 2CHIBA UNIVERSITY, CHIBA, JAPAN; 3OSAKA CITY UNIVERSITY, OSAKA, JAPAN; 4OSAKA RED CROSS HOSPITAL, OSAKA, JAPAN; 5OKAYAMA UNIVERSITY, OKAYAMA, JAPAN; 6KURUME UNIVERSITY, KURUME, JAPAN